OmicsBank raises $2.25 million seed round led by Redesign Health; Orbit backed 2025 pre-seed

By Public Technologies
  • OmicsBank raised USD 2.25 million in seed funding led by Redesign Health to expand clinical data infrastructure across the U.S., Asia, and the Middle East.
  • Orbit Startups led OmicsBank’s pre-seed round in 2025.
  • OmicsBank builds research-ready clinical datasets by standardizing fragmented hospital and lab records, targeting underrepresented populations in genomic research.
  • The network spans more than 90 hospitals and diagnostic labs across Asia, covering data from 12.5 million patients.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Orbit Startups published the original content used to generate this news brief on October 05, 2026, and is solely responsible for the information contained therein.

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.